The 2,400 Shares of Stock are sold by athenahealth Inc. (ATHN) Director Brandon H. Hull

The 2,400 Shares of Stock are sold by athenahealth Inc. (ATHN) Director Brandon H. Hull

athenahealth Inc. (NASDAQ:ATHN) Director Brandon H. Hull sold 2,400 shares of the stock in a transaction that occurred on Monday, October 10th. The shares were sold at an average price of $130.00, for a total transaction of $312,000.00. Following the completion of the sale, the director now directly owns 3,987 shares of the company’s stock, valued at approximately $518,310. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

athenahealth Inc. (NASDAQ:ATHN) opened at 127.30 on Thursday. The firm has a market capitalization of $5.01 billion, a price-to-earnings ratio of 468.01 and a beta of 1.28. The stock’s 50 day moving average price is $123.62 and its 200-day moving average price is $129.75. athenahealth Inc. has a one year low of $114.59 and a one year high of $170.42.

athenahealth (NASDAQ:ATHN) last posted its quarterly earnings data on Thursday, July 21st. The company reported $0.34 EPS for the quarter, missing analysts’ consensus estimates of $0.42 by $0.08. The business earned $261.90 million during the quarter, compared to analyst estimates of $274.07 million. athenahealth had a return on equity of 5.16% and a net margin of 1.06%. On average, equities research analysts anticipate that athenahealth Inc. will post $1.77 earnings per share for the current fiscal year.

ATHN has been the subject of several research analyst reports. Evercore ISI upgraded athenahealth from a “hold” rating to a “buy” rating and set a $152.00 target price for the company in a research note on Monday. Deutsche Bank AG cut athenahealth from a “buy” rating to a “hold” rating and reduced their target price for the company from $165.00 to $147.00 in a research note on Friday, July 22nd. Zacks Investment Research cut athenahealth from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 12th. Canaccord Genuity reiterated a “hold” rating and set a $142.00 target price on shares of athenahealth in a research note on Wednesday, June 29th. Finally, Leerink Swann reiterated a “hold” rating on shares of athenahealth in a research note on Thursday, June 16th. Four research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $149.70.

A number of institutional investors have recently bought and sold shares of the company. Advisor Group Inc. acquired a new position in athenahealth during the second quarter worth approximately $118,000. FineMark National Bank & Trust raised its position in athenahealth by 4.5% in the second quarter. FineMark National Bank & Trust now owns 944 shares of the company’s stock worth $130,000 after buying an additional 41 shares in the last quarter. KBC Group NV acquired a new position in athenahealth during the second quarter worth approximately $135,000. Societe Generale acquired a new position in athenahealth during the second quarter worth approximately $176,000. Finally, SG Americas Securities LLC raised its position in athenahealth by 27.7% in the second quarter. SG Americas Securities LLC now owns 1,277 shares of the company’s stock worth $176,000 after buying an additional 277 shares in the last quarter.

athenahealth Company Profile

Related posts

Leave a Comment